Global Recombinant Insulin Analogue Production, Demand and Key Producers, 2022-2028

November 2022 | 97 pages | ID: GD864F875A8CEN
GlobalInfoResearch

Abstracts

Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.

This report studies the global Recombinant Insulin Analogue production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Recombinant Insulin Analogue, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Recombinant Insulin Analogue that contribute to its increasing demand across many markets.

The global Recombinant Insulin Analogue market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).

Highlights and key features of the study

Global Recombinant Insulin Analogue total production and demand, 2017-2028, (K Units)

Global Recombinant Insulin Analogue total production value, 2017-2028, (USD Million)

Global Recombinant Insulin Analogue production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)

Global Recombinant Insulin Analogue consumption by region & country, CAGR, 2017-2028 & (K Units)

U.S. VS China: Recombinant Insulin Analogue domestic production, consumption, key domestic manufacturers and share

Global Recombinant Insulin Analogue production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)

Global Recombinant Insulin Analogue production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)

Global Recombinant Insulin Analogue production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)

This reports profiles key players in the global Recombinant Insulin Analogue market based on the following parameters – headquarters, production locations, products portfolio, Recombinant Insulin Analogue revenue, sales, average price and gross margin, recent developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Recombinant Insulin Analogue market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.

Global Recombinant Insulin Analogue Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India

Global Recombinant Insulin Analogue Market, Segmentation by Type

• Quick-Acting
• Medium Effect
• Long-Lasting
• Super Long-Acting

Global Recombinant Insulin Analogue Market, Segmentation by Application

• Type 1 Diabetes
• Type 2 Diabetes

Companies Profiled:

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Gan & Lee Pharmaceuticals Co., Ltd
• The United Laboratories International Holdings Limited
• Tonghua Dongbao Pharmaceutical Co., Ltd

Key Questions Answered

1. How big is the global Recombinant Insulin Analogue market?

2. What is the demand of the global Recombinant Insulin Analogue market?

3. What is the year over year growth of the global Recombinant Insulin Analogue market?

4. What is the production and production value of the global Recombinant Insulin Analogue market?

5. Who are the key producers in the global Recombinant Insulin Analogue market?

6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Recombinant Insulin Analogue Introduction
1.2 World Recombinant Insulin Analogue Supply & Forecast
  1.2.1 World Recombinant Insulin Analogue Production Value (2017 & 2021 & 2028)
  1.2.2 World Recombinant Insulin Analogue Production (2017-2028)
  1.2.3 World Recombinant Insulin Analogue Pricing Trends (2017-2028)
1.3 World Recombinant Insulin Analogue Production by Region
  1.3.1 World Recombinant Insulin Analogue Production Value by Region (2017-2028)
  1.3.2 World Recombinant Insulin Analogue Production by Region (2017-2028)
  1.3.3 World Recombinant Insulin Analogue Average Price by Region (2017-2028)
  1.3.4 North America Recombinant Insulin Analogue Production (2017-2028)
  1.3.5 Europe Recombinant Insulin Analogue Production (2017-2028)
  1.3.6 China Recombinant Insulin Analogue Production (2017-2028)
  1.3.7 Japan Recombinant Insulin Analogue Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Recombinant Insulin Analogue Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Recombinant Insulin Analogue Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
  1.5.1 Influence of COVID-19
  1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

2.1 World Recombinant Insulin Analogue Demand (2017-2028)
2.2 World Recombinant Insulin Analogue Consumption by Region
  2.2.1 World Recombinant Insulin Analogue Consumption by Region (2017-2022)
  2.2.2 World Recombinant Insulin Analogue Consumption Forecast by Region (2023-2028)
2.3 United States Recombinant Insulin Analogue Consumption (2017-2028)
2.4 China Recombinant Insulin Analogue Consumption (2017-2028)
2.5 Europe Recombinant Insulin Analogue Consumption (2017-2028)
2.6 Japan Recombinant Insulin Analogue Consumption (2017-2028)
2.7 South Korea Recombinant Insulin Analogue Consumption (2017-2028)
2.8 ASEAN Recombinant Insulin Analogue Consumption (2017-2028)
2.9 India Recombinant Insulin Analogue Consumption (2017-2028)

3 WORLD RECOMBINANT INSULIN ANALOGUE MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Recombinant Insulin Analogue Production Value by Manufacturer (2017-2022)
3.2 World Recombinant Insulin Analogue Production by Manufacturer (2017-2022)
3.3 World Recombinant Insulin Analogue Average Price by Manufacturer (2017-2022)
3.4 Recombinant Insulin Analogue Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
  3.5.1 Global Recombinant Insulin Analogue Industry Rank of Major Manufacturers
  3.5.2 Global Concentration Ratios (CR4) for Recombinant Insulin Analogue in 2021
  3.5.3 Global Concentration Ratios (CR8) for Recombinant Insulin Analogue in 2021
3.6 Recombinant Insulin Analogue Market: Overall Company Footprint Analysis
  3.6.1 Recombinant Insulin Analogue Market: Region Footprint
  3.6.2 Recombinant Insulin Analogue Market: Company Product Type Footprint
  3.6.3 Recombinant Insulin Analogue Market: Company Product Application Footprint
3.7 Competitive Environment
  3.7.1 Historical Structure of the Industry
  3.7.2 Barriers of Market Entry
  3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Recombinant Insulin Analogue Production Value Comparison
  4.1.1 United States VS China: Recombinant Insulin Analogue Production Value Comparison (2017 & 2021 & 2028)
  4.1.2 United States VS China: Recombinant Insulin Analogue Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: Recombinant Insulin Analogue Production Comparison
  4.2.1 United States VS China: Recombinant Insulin Analogue Production Comparison (2017 & 2021 & 2028)
  4.2.2 United States VS China: Recombinant Insulin Analogue Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: Recombinant Insulin Analogue Consumption Comparison
  4.3.1 United States VS China: Recombinant Insulin Analogue Consumption Comparison (2017 & 2021 & 2028)
  4.3.2 United States VS China: Recombinant Insulin Analogue Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States Recombinant Insulin Analogue Key Producers and Market Share, 2017-2022
  4.4.1 Major Manufacturer of Recombinant Insulin Analogue in United States, Company Headquarters and Production Place (States, Country)
  4.4.2 United States Recombinant Insulin Analogue Production Value by Domestic Manufacturer, (2017-2022)
  4.4.3 United States Recombinant Insulin Analogue Production by Domestic Manufacturer, (2017-2022)
4.5 China Recombinant Insulin Analogue Key Producers and Market Share, 2017-2022
  4.5.1 Major Manufacturer of Recombinant Insulin Analogue in China, Company Headquarters and Production Place (Province, Country)
  4.5.2 China Recombinant Insulin Analogue Production Value by Domestic Manufacturer, (2017-2022)
  4.5.3 China Recombinant Insulin Analogue Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World Recombinant Insulin Analogue Key Producers and Market Share, 2017-2022
  4.6.1 Major Manufacturer of Recombinant Insulin Analogue in Rest of World, Company Headquarters and Production Place (State, Country)
  4.6.2 Rest of World Recombinant Insulin Analogue Production Value by Domestic Manufacturer, (2017-2022)
  4.6.3 Rest of World Recombinant Insulin Analogue Production by Domestic Manufacturer, (2017-2022)

5 MARKET ANALYSIS BY TYPE

5.1 World Recombinant Insulin Analogue Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
  5.2.1 Quick-Acting
  5.2.2 Medium Effect
  5.2.3 Long-Lasting
  5.2.4 Super Long-Acting
5.3 Market Segment by Type
  5.3.1 World Recombinant Insulin Analogue Production by Type (2017-2028)
  5.3.2 World Recombinant Insulin Analogue Production Value by Type (2017-2028)
  5.3.3 World Recombinant Insulin Analogue Average Price by Type (2017-2028)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Recombinant Insulin Analogue Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
  6.2.1 Type 1 Diabetes
  6.2.2 Type 2 Diabetes
6.3 Market Segment by Application
  6.3.1 World Recombinant Insulin Analogue Production by Application (2017-2028)
  6.3.2 World Recombinant Insulin Analogue Production Value by Application (2017-2028)
  6.3.3 World Recombinant Insulin Analogue Average Price by Application (2017-2028)

7 COMPANY PROFILES

7.1 Novo Nordisk A/S
  7.1.1 Novo Nordisk A/S Details
  7.1.2 Novo Nordisk A/S Major Business
  7.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Product and Services
  7.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Production, Price, Value, Gross Margin and Market Share (2017-2022)
  7.1.5 Novo Nordisk A/S Recent Developments/Updates
  7.1.6 Novo Nordisk A/S Competitive Strengths & Weaknesses
7.2 Eli Lilly and Company
  7.2.1 Eli Lilly and Company Details
  7.2.2 Eli Lilly and Company Major Business
  7.2.3 Eli Lilly and Company Recombinant Insulin Analogue Product and Services
  7.2.4 Eli Lilly and Company Recombinant Insulin Analogue Production, Price, Value, Gross Margin and Market Share (2017-2022)
  7.2.5 Eli Lilly and Company Recent Developments/Updates
  7.2.6 Eli Lilly and Company Competitive Strengths & Weaknesses
7.3 Sanofi
  7.3.1 Sanofi Details
  7.3.2 Sanofi Major Business
  7.3.3 Sanofi Recombinant Insulin Analogue Product and Services
  7.3.4 Sanofi Recombinant Insulin Analogue Production, Price, Value, Gross Margin and Market Share (2017-2022)
  7.3.5 Sanofi Recent Developments/Updates
  7.3.6 Sanofi Competitive Strengths & Weaknesses
7.4 Gan & Lee Pharmaceuticals Co., Ltd
  7.4.1 Gan & Lee Pharmaceuticals Co., Ltd Details
  7.4.2 Gan & Lee Pharmaceuticals Co., Ltd Major Business
  7.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product and Services
  7.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Production, Price, Value, Gross Margin and Market Share (2017-2022)
  7.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates
  7.4.6 Gan & Lee Pharmaceuticals Co., Ltd Competitive Strengths & Weaknesses
7.5 The United Laboratories International Holdings Limited
  7.5.1 The United Laboratories International Holdings Limited Details
  7.5.2 The United Laboratories International Holdings Limited Major Business
  7.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product and Services
  7.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Production, Price, Value, Gross Margin and Market Share (2017-2022)
  7.5.5 The United Laboratories International Holdings Limited Recent Developments/Updates
  7.5.6 The United Laboratories International Holdings Limited Competitive Strengths & Weaknesses
7.6 Tonghua Dongbao Pharmaceutical Co., Ltd
  7.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Details
  7.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Major Business
  7.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product and Services
  7.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Production, Price, Value, Gross Margin and Market Share (2017-2022)
  7.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments/Updates
  7.6.6 Tonghua Dongbao Pharmaceutical Co., Ltd Competitive Strengths & Weaknesses

8 RAW MATERIAL AND INDUSTRY CHAIN

8.1 Raw Material of Recombinant Insulin Analogue and Key Manufacturers
8.2 Recombinant Insulin Analogue Manufacturing Costs
8.3 Recombinant Insulin Analogue Production Process
8.4 Recombinant Insulin Analogue Industrial Chain

9 DISTRIBUTION CHANNEL ANALYSIS

9.1 Distribution Channel Breakdown for Recombinant Insulin Analogue Shipments (%): 2017-2028
  9.1.1 Direct Channel
  9.1.2 Indirect Channel
9.2 Recombinant Insulin Analogue Typical Distributors
9.3 Recombinant Insulin Analogue Typical Customers

10 RESEARCH FINDINGS AND CONCLUSION

11 APPENDIX

11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Recombinant Insulin Analogue Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Recombinant Insulin Analogue Production Value by Region (2017-2022) & (USD Million)
Table 3. World Recombinant Insulin Analogue Production Value by Region (2023-2028) & (USD Million)
Table 4. World Recombinant Insulin Analogue Production Value Market Share by Region (2017-2022)
Table 5. World Recombinant Insulin Analogue Production Value Market Share by Region (2023-2028)
Table 6. World Recombinant Insulin Analogue Production by Region (2017-2022) & (K Units)
Table 7. World Recombinant Insulin Analogue Production by Region (2023-2028) & (K Units)
Table 8. World Recombinant Insulin Analogue Production Market Share by Region (2017-2022)
Table 9. World Recombinant Insulin Analogue Production Market Share by Region (2023-2028)
Table 10. World Recombinant Insulin Analogue Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World Recombinant Insulin Analogue Average Price by Region (2023-2028) & (US$/Unit)
Table 12. Recombinant Insulin Analogue Major Market Trends
Table 13. World Recombinant Insulin Analogue Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World Recombinant Insulin Analogue Consumption by Region (2017-2022) & (K Units)
Table 15. World Recombinant Insulin Analogue Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World Recombinant Insulin Analogue Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key Recombinant Insulin Analogue Producers in 2021
Table 18. World Recombinant Insulin Analogue Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key Recombinant Insulin Analogue Producers in 2021
Table 20. World Recombinant Insulin Analogue Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global Recombinant Insulin Analogue Company Evaluation Quadrant
Table 22. World Recombinant Insulin Analogue Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and Recombinant Insulin Analogue Production Site of Key Manufacturer
Table 24. Recombinant Insulin Analogue Market: Company Product Type Footprint
Table 25. Recombinant Insulin Analogue Market: Company Product Application Footprint
Table 26. Recombinant Insulin Analogue Competitive Factors
Table 27. Recombinant Insulin Analogue New Entrant and Capacity Expansion Plans
Table 28. Recombinant Insulin Analogue Mergers & Acquisitions Activity
Table 29. United States VS China Recombinant Insulin Analogue Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China Recombinant Insulin Analogue Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China Recombinant Insulin Analogue Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of Recombinant Insulin Analogue in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States Recombinant Insulin Analogue Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States Recombinant Insulin Analogue Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States Recombinant Insulin Analogue Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States Recombinant Insulin Analogue Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of Recombinant Insulin Analogue in China, Company Headquarters and Production Place (Province, Country)
Table 38. China Recombinant Insulin Analogue Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China Recombinant Insulin Analogue Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China Recombinant Insulin Analogue Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China Recombinant Insulin Analogue Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of Recombinant Insulin Analogue in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World Recombinant Insulin Analogue Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World Recombinant Insulin Analogue Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World Recombinant Insulin Analogue Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World Recombinant Insulin Analogue Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World Recombinant Insulin Analogue Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World Recombinant Insulin Analogue Production by Type (2017-2022) & (K Units)
Table 49. World Recombinant Insulin Analogue Production by Type (2023-2028) & (K Units)
Table 50. World Recombinant Insulin Analogue Production Value by Type (2017-2022) & (USD Million)
Table 51. World Recombinant Insulin Analogue Production Value by Type (2023-2028) & (USD Million)
Table 52. World Recombinant Insulin Analogue Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World Recombinant Insulin Analogue Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World Recombinant Insulin Analogue Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World Recombinant Insulin Analogue Production by Application (2017-2022) & (K Units)
Table 56. World Recombinant Insulin Analogue Production by Application (2023-2028) & (K Units)
Table 57. World Recombinant Insulin Analogue Production Value by Application (2017-2022) & (USD Million)
Table 58. World Recombinant Insulin Analogue Production Value by Application (2023-2028) & (USD Million)
Table 59. World Recombinant Insulin Analogue Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World Recombinant Insulin Analogue Average Price by Application (2023-2028) & (US$/Unit)
Table 61. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 62. Novo Nordisk A/S Major Business
Table 63. Novo Nordisk A/S Recombinant Insulin Analogue Product and Services
Table 64. Novo Nordisk A/S Recombinant Insulin Analogue Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. Novo Nordisk A/S Recent Developments/Updates
Table 66. Novo Nordisk A/S Competitive Strengths & Weaknesses
Table 67. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 68. Eli Lilly and Company Major Business
Table 69. Eli Lilly and Company Recombinant Insulin Analogue Product and Services
Table 70. Eli Lilly and Company Recombinant Insulin Analogue Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Eli Lilly and Company Recent Developments/Updates
Table 72. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 73. Sanofi Basic Information, Manufacturing Base and Competitors
Table 74. Sanofi Major Business
Table 75. Sanofi Recombinant Insulin Analogue Product and Services
Table 76. Sanofi Recombinant Insulin Analogue Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Sanofi Recent Developments/Updates
Table 78. Sanofi Competitive Strengths & Weaknesses
Table 79. Gan & Lee Pharmaceuticals Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 80. Gan & Lee Pharmaceuticals Co., Ltd Major Business
Table 81. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product and Services
Table 82. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates
Table 84. Gan & Lee Pharmaceuticals Co., Ltd Competitive Strengths & Weaknesses
Table 85. The United Laboratories International Holdings Limited Basic Information, Manufacturing Base and Competitors
Table 86. The United Laboratories International Holdings Limited Major Business
Table 87. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product and Services
Table 88. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. The United Laboratories International Holdings Limited Recent Developments/Updates
Table 90. Tonghua Dongbao Pharmaceutical Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 91. Tonghua Dongbao Pharmaceutical Co., Ltd Major Business
Table 92. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product and Services
Table 93. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 94. Recombinant Insulin Analogue Raw Material
Table 95. Key Manufacturers of Recombinant Insulin Analogue Raw Materials
Table 96. Recombinant Insulin Analogue Typical Distributors
Table 97. Recombinant Insulin Analogue Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Recombinant Insulin Analogue Picture
Figure 2. World Recombinant Insulin Analogue Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Recombinant Insulin Analogue Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World Recombinant Insulin Analogue Production (2017-2028) & (K Units)
Figure 5. World Recombinant Insulin Analogue Average Price (2017-2028) & (US$/Unit)
Figure 6. World Recombinant Insulin Analogue Production Value Market Share by Region (2017-2028)
Figure 7. World Recombinant Insulin Analogue Production Market Share by Region (2017-2028)
Figure 8. North America Recombinant Insulin Analogue Production (2017-2028) & (K Units)
Figure 9. Europe Recombinant Insulin Analogue Production (2017-2028) & (K Units)
Figure 10. China Recombinant Insulin Analogue Production (2017-2028) & (K Units)
Figure 11. Japan Recombinant Insulin Analogue Production (2017-2028) & (K Units)
Figure 12. Recombinant Insulin Analogue Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Recombinant Insulin Analogue Demand (2017-2028) & (K Units)
Figure 15. World Recombinant Insulin Analogue Consumption Market Share by Region (2017-2028)
Figure 16. United States Recombinant Insulin Analogue Consumption (2017-2028) & (K Units)
Figure 17. China Recombinant Insulin Analogue Consumption (2017-2028) & (K Units)
Figure 18. Europe Recombinant Insulin Analogue Consumption (2017-2028) & (K Units)
Figure 19. Japan Recombinant Insulin Analogue Consumption (2017-2028) & (K Units)
Figure 20. South Korea Recombinant Insulin Analogue Consumption (2017-2028) & (K Units)
Figure 21. ASEAN Recombinant Insulin Analogue Consumption (2017-2028) & (K Units)
Figure 22. India Recombinant Insulin Analogue Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of Recombinant Insulin Analogue by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for Recombinant Insulin Analogue Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for Recombinant Insulin Analogue Markets in 2021
Figure 26. United States VS China: Recombinant Insulin Analogue Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: Recombinant Insulin Analogue Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: Recombinant Insulin Analogue Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of Recombinant Insulin Analogue in United States
Figure 30. Key Producers and Market Share of Recombinant Insulin Analogue in China
Figure 31. Key Producers and Market Share of Recombinant Insulin Analogue in Rest of World
Figure 32. World Recombinant Insulin Analogue Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World Recombinant Insulin Analogue Production Value Market Share by Type in 2021
Figure 34. Quick-Acting
Figure 35. Medium Effect
Figure 36. Long-Lasting
Figure 37. Super Long-Acting
Figure 38. World Recombinant Insulin Analogue Production Market Share by Type (2017-2028)
Figure 39. World Recombinant Insulin Analogue Production Value Market Share by Type (2017-2028)
Figure 40. World Recombinant Insulin Analogue Average Price by Type (2017-2028) & (US$/Unit)
Figure 41. World Recombinant Insulin Analogue Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 42. World Recombinant Insulin Analogue Production Value Market Share by Application in 2021
Figure 43. Type 1 Diabetes
Figure 44. Type 2 Diabetes
Figure 45. World Recombinant Insulin Analogue Production Market Share by Application (2017-2028)
Figure 46. World Recombinant Insulin Analogue Production Value Market Share by Application (2017-2028)
Figure 47. World Recombinant Insulin Analogue Average Price by Application (2017-2028) & (US$/Unit)
Figure 48. Manufacturing Cost Structure Analysis of Recombinant Insulin Analogue in 2021
Figure 49. Manufacturing Process Analysis of Recombinant Insulin Analogue
Figure 50. Recombinant Insulin Analogue Industrial Chain
Figure 51. Distribution Channel Breakdown for Recombinant Insulin Analogue Shipments (%): 2017-2028
Figure 52. Direct Channel Pros & Cons
Figure 53. Indirect Channel Pros & Cons
Figure 54. Methodology
Figure 55. Research Process and Data Source